A primary challenge in oncology vaccinology is delivering payloads to lymphoid-resident antigen-presenting cells (APCs) without triggering systemic toxicities or rapid hepatic clearance. While synthetic lipid nanoparticles (LNPs) are standard for systemic delivery, they face hepatocyte sequestration driven by blood-borne apolipoprotein E (ApoE) binding, which limits extrahepatic bioavailability. To bypass this constraint, engineered exosomes offer a biological alternative. These cell-derived vesicles feature a native lipid bilayer enriched with cholesterol and sphingomyelin that shields mRNA from ribonuclease degradation. By presenting surface markers like CD47—a “don’t eat me” signal blocking macrophage phagocytosis via SIRPα—exosomes achieve extended circulation half-lives (
Figure 1).
When administered via intramuscular (IM) injection, these mRNA-loaded exosomes induce local inflammation at the injection site. This acute inflammatory microenvironment recruits host immune cells and triggers a localized cytokine release governed by mRNA-mediated epigenetic regulation. Following antigen acquisition, these recruited immune cells migrate into regional lymph nodes for further activation and clonal expansion. The resulting activated effector lineages then traffic directly into the TME, turning the immunologically “cold” stroma into an active, inflamed “hot” niche to drive tumor cell death. This cellular remodeling allows cytotoxic CD8
+ T cells and natural killer (NK) cells to aggressively clear the malignancy. Crucially, this inflamed state sensitizes the tumor to clinical immune checkpoint inhibitors (ICIs).
In a review (DOI: 10.1093/pcmedi/pbag019) published on Jul. 7, 2026, in
Precision Clinical Medicine, researchers from Case Western Reserve University School of Medicine, a pioneering force in molecular oncology, elaborated how combining personalized tumor neoantigens with bioengineered extracellular vesicles can overcome immunotherapeutic resistance. This review titled “
Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines” provides a mechanistic blueprint showing how these customized mRNA payloads can systematically reprogram the immunosuppressive architecture of “cold” tumor microenvironments (TMEs) and mobilize potent, antigen-specific cytotoxic T-lymphocyte (CTL) responses.
While antiviral mRNA therapeutics have proven the utility of nucleic acid platforms, translating this technology to aggressive solid malignancies remains difficult due to local immune tolerance. Malignant niches actively exclude effector cells by erecting physical extracellular matrix barriers, altering localized biochemical signaling, and recruiting regulatory leukocyte populations (
Figure 2). This review highlights how combining multivalent mRNA payloads with surface-functionalized exosomes can disrupt these barriers to ignite durable anti-tumor immunity.
The review underscores that long-term anti-tumor durability is sustained via intranuclear epigenetic priming rather than altering the underlying genetic code. The vaccine-induced cytokine network drives precise chromatin remodeling within both myeloid and lymphoid lineages. Through specific histone modifications, such as the enrichment of H3K27ac at promoter regions, and targeted DNA demethylation of the IFNG and GZMB promoters, the platform successfully establishes trained innate immunity and expands central and tissue-resident memory T-cell pools. This heightened chromatin accessibility ensures that peripheral immune effectors remain transcriptionally poised to execute rapid recall programs upon tumor re-encounter. However, maintaining chromatin in a hyper-accessible state requires strict temporal control to prevent chronic low-grade inflammation or autoimmune activation against healthy tissues. Clinical translation requires replacing laboratory ultracentrifugation with cGMP-compliant tangential flow filtration (TFF) and size-exclusion chromatography (SEC) to resolve vesicle heterogeneity. The goal is to establish pre-manufactured, modular exosome chassis rapidly loaded with patient-specific multiomic neoantigen libraries, making personalized precision medicine a scalable reality.
DOI：